Atty Dkt No. PXE-012.US USSN: 09/465,978 PATENT

USPQ 214 (CCPA 1976). Thus, applicants reiterate that the test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the patent coupled with information known in the art without undue experimentation. *Ex parte Forman*, 230 USPQ 546 (P.T.O. Bd. Pat. App. & Int., 1986).

The Declaration submitted herewith documents that transgenic mice as recited in the pending claims were generated using methods and sequences set forth in the specification and/or coupled with methods well-known in the art. Further, the mice produced by the methods have been shown to exhibit the desired characteristics. Thus, Dr. Zhang states:

8. It is known that VEGFR-2 is expressed during angiogenesis and is regarded as an angiogenesis marker. (See, e.g., page 24, line 21 to page 22, line 21 of the specification). In addition, it is known that the process of angiogenesis is very active during embryonic development and in the early stages of post-natal development. Accordingly, the transgenic mice containing SEQ ID NO:32 operably linked to a sequence encoding light-generating protein (e.g., luciferase) were evaluated for luciferase expression in vivo from 1 week until 6 weeks of age, essentially using methods described on page 24, lines 19-21 and page 45, lines 8-24 of the specification. All the four founder lines expressed high level of luciferase activity in the entire body when 1-week-old mice were imaged. The activities declined rapidly (by up to 7000 fold) over time and by 6 week after birth, the luciferase activity dropped to a basal level (Exhibit B. Figure 2a). These results demonstrate that VEGFR-2 expression can be monitored in transgenic mice containing a sequence encoding a light-generating protein which is operably linked to the regulatory sequence of SEQ ID NO:32 and that development-dependent reduction of luciferase activity mimicked the change of angiogenesis activity during post-natal development. Thus, transgenic mice prepared according to the teachings of the specification can be used to monitor angiogenesis in vivo and can be used to screen the effect of a compound on angiogenesis.

Therefore, as indicated in the attached Declaration, the teachings of the specification are more than sufficient to enable one of skill in the art to make and use the claimed subject matter.

Atty Dkt No. PXE-012.US USSN: 09/465,978 PATENT

3. Conclusion

For the foregoing reasons, applicants believe the claims are in condition for allowance and request early notification to that effect. If the Examiner notes any further matters that the Examiner believes may be expedited by a telephone interview, the Examiner is requested to contact the undersigned at (650) 325-7812.

Respectfully submitted,

Date: 14 Jan Zooz


Gary R. Fabian, Ph.D.

Agent for Applicants

Registration No. 33,875

ROBINS & PASTERNAK LLP 90 Middlefield Road, Suite 200 Menlo Park, CA 94025 Telephone: (650) 325-7812

Fax: (650) 325-7823



Currently Pending Claims

1-27. (Canceled).

- 28. (New) A transgenic mouse or progeny thereof, comprising an expression cassette comprising a cis-acting transcription regulator operably linked to a reporter sequence encoding a light-generating protein, wherein said cis-acting transcription regulator consists of the sequence presented as SEQ ID NO:32.
- 29. (New) The transgenic mouse of claim 28, wherein said light-generating protein is a luciferase.

APACENTE CONTROL OF THE CONTROL OF T